Your browser is no longer supported. Please, upgrade your browser.
Settings
WINT [NASD]
Windtree Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.29 Insider Own0.50% Shs Outstand16.58M Perf Week-17.78%
Market Cap72.44M Forward P/E- EPS next Y-1.84 Insider Trans4.04% Shs Float4.47M Perf Month-21.51%
Income-32.50M PEG- EPS next Q-0.45 Inst Own4.00% Short Float1.91% Perf Quarter-33.97%
Sales0.00M P/S- EPS this Y89.20% Inst Trans-8.22% Short Ratio1.85 Perf Half Y-47.83%
Book/sh4.57 P/B0.95 EPS next Y12.40% ROA-27.10% Target Price- Perf Year-65.67%
Cash/sh- P/C- EPS next 5Y- ROE-42.70% 52W Range4.00 - 12.00 Perf YTD-15.69%
Dividend- P/FCF- EPS past 5Y64.30% ROI-28.20% 52W High-63.96% Beta-0.08
Dividend %- Quick Ratio3.80 Sales past 5Y-41.30% Gross Margin- 52W Low8.12% ATR0.34
Employees31 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)21.18 Volatility9.04% 5.39%
OptionableNo Debt/Eq0.24 EPS Q/Q18.10% Profit Margin- Rel Volume3.50 Prev Close4.94
ShortableYes LT Debt/Eq0.23 Earnings- Payout- Avg Volume46.17K Price4.32
Recom1.00 SMA20-20.01% SMA50-21.23% SMA200-34.87% Volume153,975 Change-12.45%
Jun-26-20Initiated Ladenburg Thalmann Buy $12.25
Feb-22-21 08:18AM  
Feb-16-21 07:00AM  
Feb-04-21 08:30AM  
Feb-01-21 04:30PM  
Jan-06-21 08:00AM  
Nov-24-20 06:15AM  
Nov-16-20 07:45AM  
Oct-01-20 07:30AM  
Sep-29-20 07:30AM  
Sep-08-20 08:00AM  
Aug-31-20 12:06PM  
Aug-13-20 07:36PM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jun-30-20 08:43AM  
Jun-24-20 08:00AM  
May-28-20 08:00AM  
May-22-20 04:05PM  
May-20-20 08:30AM  
May-14-20 08:00AM  
Apr-29-20 07:45AM  
Apr-28-20 04:05PM  
Apr-06-20 07:45AM  
Apr-02-20 07:30PM  
Mar-31-20 07:45AM  
Mar-24-20 07:45AM  
Dec-09-19 08:00AM  
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fraser CraigPresident and CEOOct 28Buy6.562501,64024,298Oct 29 06:08 AM
Huang JamesDirectorOct 23Buy6.671,0006,66621,000Oct 27 06:02 AM
Fraser CraigPresident and CEOOct 09Buy5.832501,45624,048Oct 13 08:40 AM
Curtis EricSVP & COOOct 08Buy5.275002,635500Oct 09 08:03 AM
Hamill John P.SVP & CFOOct 07Buy5.271,0005,2701,000Oct 09 08:06 AM
Fraser CraigPresident and CEOOct 07Buy5.172501,29323,798Oct 09 08:05 AM
Huang JamesDirectorJun 04Buy7.3212,20089,33220,200Jun 05 08:36 PM
Huang JamesDirectorJun 03Buy7.422001,4848,000Jun 05 08:36 PM